Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Incannex Healthcare Inc.IXHL · Entity 7349 | Director | November 14, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Incannex Healthcare Inc.
Report date November 14, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 1,957,803 |
Reported balance
After 2025-11-14 transaction · row 1
1 source rowRow 1 · 2025-11-14 · Grant · Acquired 1,686,956 · Balance 1,957,803 F1: Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2025 Filed Nov 14, 2025 06:15 UTC | Incannex Healthcare Inc. IXHL · Entity 7349 | GrantCommon Stock, $0.0001 par value per share | 1,686,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-110284 · ownership.xml · nonDerivative · entry 1 Widdows Peter · CIK 0001997183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,957,803 F1 · shares: Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027. Read SEC document |
| December 21, 2023 Filed Dec 21, 2023 20:53 UTC | Incannex Healthcare Inc. IXHL · Entity 7349 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-097818 · ownership.xml · nonDerivative · entry 1 Widdows Peter · CIK 0001997183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,847 F1 · kind: Award of restricted stock of which 25,000 shares will vest on December 31, 2023, 25,000 shares concerning the remuneration of fiscal year 2023 will vest on June 30, 2024, 25,000 shares concerning the remuneration of fiscal year 2024 will vest on June 30, 2024, and 25,000 shares will vest on June 30, 2025, based upon the Reporting Person's continuing service as director on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.